OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients with ATTR Amyloidosis

Trial Identifier: D8450R00004
Sponsor: AstraZeneca
Start Date: August 2023
Primary Completion Date: September 2026
Study Completion Date: September 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Alberta Calgary, Alberta, Canada, T2P 4K7
China Beijing, China
China Changsha, China
China Chengdu, China
China Guangzhou, China
China Wuhan, China
Denmark Horsens, Denmark
Germany Berlin, Germany
Japan Tokyo, Japan
Portugal Lisbona, Portugal
Portugal Porto, Portugal
Spain A Coruna, Spain
Spain Barcelona, Spain
Spain Bilbao, Spain
Spain El Palmar, Spain
Spain Huelva, Spain
Spain Las Palmas de Gran Canaria, Spain
Spain Madrid, Spain
Spain Majadahonda, Spain
Spain Palma de Mallorca, Spain
Spain Salamanca, Spain
Spain Valencia, Spain
Sweden Sodertalje, Sweden
Sweden Umea, Sweden
UK London, UK
USA, Minnesota Eden Prairie, Minnesota, USA, 55344